These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 1732427

  • 1. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.
    Jacobs C, Lyman G, Velez-García E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L.
    J Clin Oncol; 1992 Feb; 10(2):257-63. PubMed ID: 1732427
    [Abstract] [Full Text] [Related]

  • 2. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
    Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, Forastiere AA, Eastern Cooperative Oncology Group.
    J Clin Oncol; 2005 May 20; 23(15):3562-7. PubMed ID: 15908667
    [Abstract] [Full Text] [Related]

  • 3. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.
    Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK.
    J Clin Oncol; 1992 Aug 20; 10(8):1245-51. PubMed ID: 1634913
    [Abstract] [Full Text] [Related]

  • 4. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group.
    Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, Tueni EA, Verweij J, Wildiers J, Clerico M.
    Ann Oncol; 1994 Jul 20; 5(6):521-6. PubMed ID: 7522527
    [Abstract] [Full Text] [Related]

  • 5. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
    Hussain M, Gadgeel S, Kucuk O, Du W, Salwen W, Ensley J.
    Cancer; 1999 Dec 01; 86(11):2364-9. PubMed ID: 10590379
    [Abstract] [Full Text] [Related]

  • 6. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Bourhis J, Rivera F, Mesia R, Awada A, Geoffrois L, Borel C, Humblet Y, Lopez-Pousa A, Hitt R, Vega Villegas ME, Duck L, Rosine D, Amellal N, Schueler A, Harstrick A.
    J Clin Oncol; 2006 Jun 20; 24(18):2866-72. PubMed ID: 16717293
    [Abstract] [Full Text] [Related]

  • 7. A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck.
    Caponigro F, Comella P, Marcolin P, Russo Spena F, Biglietto M, Cartenì G, De Lucia L, Avallone A, Gravina A, Comella G.
    Cancer; 1999 Feb 15; 85(4):952-9. PubMed ID: 10091775
    [Abstract] [Full Text] [Related]

  • 8. Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Paredes J, Hong WK, Felder TB, Dimery IW, Choksi AJ, Newman RA, Castellanos AM, Robbins KT, McCarthy K, Atkinson N.
    J Clin Oncol; 1988 Jun 15; 6(6):955-62. PubMed ID: 2836565
    [Abstract] [Full Text] [Related]

  • 9. Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy.
    Recondo G, Armand JP, Tellez-Bernal E, Domenge C, Belehradek M, De Vathaire F, Wibault P, Richard JM, Cvitkovic E.
    Laryngoscope; 1991 May 15; 101(5):494-501. PubMed ID: 1709437
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
    Worden FP, Moon J, Samlowski W, Clark JI, Dakhil SR, Williamson S, Urba SG, Ensley J, Hussain MH, Southwest Oncology Group, Head and Neck Working Group.
    Cancer; 2006 Jul 15; 107(2):319-27. PubMed ID: 16779801
    [Abstract] [Full Text] [Related]

  • 12. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
    Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP.
    J Clin Oncol; 1998 May 15; 16(5):1826-34. PubMed ID: 9586897
    [Abstract] [Full Text] [Related]

  • 13. Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience.
    Papadimitrakopoulou VA, Dimery IW, Lee JJ, Perez C, Hong WK, Lippman SM.
    Cancer J Sci Am; 1997 May 15; 3(2):92-9. PubMed ID: 9099459
    [Abstract] [Full Text] [Related]

  • 14. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
    Kiyota N, Tahara M, Kadowaki S, Fuse N, Doi T, Minami H, Ohtsu A.
    Jpn J Clin Oncol; 2009 Apr 15; 39(4):225-30. PubMed ID: 19211574
    [Abstract] [Full Text] [Related]

  • 15. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
    Rapidis AD, Trichas M, Stavrinidis E, Roupakia A, Ioannidou G, Kritselis G, Liossi P, Giannakouras G, Douzinas EE, Katsilieris I.
    Oral Oncol; 2006 Aug 15; 42(7):675-84. PubMed ID: 16731029
    [Abstract] [Full Text] [Related]

  • 16. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, Foa P, Rottey S, Skladowski K, Tahara M, Pai VR, Faivre S, Blajman CR, Forastiere AA, Stein BN, Oliner KS, Pan Z, Bach BA, SPECTRUM investigators.
    Lancet Oncol; 2013 Jul 15; 14(8):697-710. PubMed ID: 23746666
    [Abstract] [Full Text] [Related]

  • 17. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial.
    Colevas AD, Busse PM, Norris CM, Fried M, Tishler RB, Poulin M, Fabian RL, Fitzgerald TJ, Dreyfuss A, Peters ES, Adak S, Costello R, Barton JJ, Posner MR.
    J Clin Oncol; 1998 Apr 15; 16(4):1331-9. PubMed ID: 9552034
    [Abstract] [Full Text] [Related]

  • 18. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
    Cho H, Nishiike S, Yamamoto Y, Takenaka Y, Nakahara S, Yasui T, Hanamoto A, Inohara H.
    Auris Nasus Larynx; 2015 Oct 15; 42(5):396-400. PubMed ID: 25721854
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.